Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can AI make acupuncture more precise for allergy relief?

NCT ID NCT07778537

Disease control Sponsor: Daxing Teaching Hospital, Capital Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 21, 2026 · Last updated Aug 21, 2026

Summary

This trial tests whether artificial intelligence can help acupuncturists hit a deep facial point, called the Xinwu point, more accurately when treating allergic rhinitis (hay fever-like nasal allergies). Sixty adults will be randomly assigned to receive either AI-guided needling using ultrasound or the usual blind method. Both groups get the same treatment schedule: needles on both sides of the face, once a week for six sessions. The study will measure how often the needle reaches the target, as well as side effects and changes in nasal symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AI-guided acupuncture at the Xinwu point (sphenopalatine ganglion) using ultrasound and an AI anatomical-recognition program, compared with conventional blind needling.
What this could lead to
If successful, this could make acupuncture more precise and potentially more effective for allergic rhinitis, offering a new option for symptom relief.
What could go wrong
This is a small early-stage trial, and the main focus is on needle accuracy rather than long-term symptom improvement. Results may not generalize, and acupuncture carries risks like pain or bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Started

Sep 2025

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of allergic rhinitis according to the Chinese Guideline for the Diagnosis and Treatment of Allergic Rhinitis (2022, revised edition) * Age 18 to 60 years * No acupuncture or anti-allergic medication other than the study intervention within the preceding week * Written informed consent and ability to complete treatment and follow-up Exclusion Criteria: * Serious underlying diseases of the heart, brain, liver, or kidney * Systemic corticosteroid use or allergen immunotherapy within the preceding 3 months * Other nasal disorders such as sinusitis, nasal polyps, or marked nasal septum deviation * Coagulation abnormalities or long-term use of anticoagulants (e.g., warfarin or aspirin) * Pregnancy, lactation, or planned pregnancy * Impaired consciousness or verbal expression precluding cooperation with assessment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Allergic rhinitis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

allergic rhinitis Rhinitis, Allergic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Allergic rhinitis Rhinitis, allergic

Contacts and locations

Locations

  • Daxing Teaching Hospital of Capital Medical University

    Beijing, Beijing Municipality, 102600, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.